<DOC>
	<DOCNO>NCT01662050</DOCNO>
	<brief_summary>A phase 2 study standard R‐BAC ( rituximab 375 mg/m2 , bendamustine 70 mg/m2 , ara‐c 800 mg/m2 ) recently ultimated Vicenza Hematology Department involve several regional center untreated previously treat patient Mantle Cell Lymphoma ( MCL ) . An interim analysis conduct 30 patient show rituximab + bendamustine + ara‐c combination good clinical activity , quite relevant hematological toxicity , especially previously treat old patient ( Visco C , ICML 2011 Lugano Conference , Poster 236 ) . Objectives : The primary objective determine activity ( complete remission rate accord Cheson 2007 criterion ) safety age‐adjusted Rituximab‐Bendamustine‐Cytarabine ( RBAC500 ) regimen end treatment old untreated patient MCL . The secondary objective determine : - The rate molecular response ( characterized lab FIL ) - The progression‐free survival ( PFS ) - The overall survival ( OS ) - The duration response ( DOR ) - The rate patient complete expect treatment schedule ( 6 course ) - The rate patient subject dose reduction delay</brief_summary>
	<brief_title>Phase II Study Age‐Adjusted Rituximab , Bendamustine , Cytarabine Induction Therapy Older Patients With Mantle Cell Lymphoma</brief_title>
	<detailed_description>Study End point Primary efficacy end point study proportion CR define accord Cheson criterion ( 2007 ) end treatment ( 6 4 cycle ) . Primary safety end point occurrence stop treatment criterion episode relevant toxicity , define . Secondary end point MRD define response , OS , PFS DOR ( Cheson 2007 ) . Molecular response proportion patient molecular rearrangement baseline become negative treatment , measure qualitative quantitative PCR . OS measure enrollment death cause . PFS measure time enrollment disease progression , relapse death cause . DOR measure first assessment document response ( CR PR ) date disease relapse progression . Minimum follow require patient 24 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Previously untreated patient MCL age &gt; 65 year FIT accord geriatric CGA assessment . age 6065 year eligible highdose chemotherapy plus transplantation , FIT UNFIT accord geriatric CGA assessment . ECOG performance status ≤ 2 . Positivity cyclin D1 SOX11 [ latter mandatory case lack cyclin D1 ( 11 ; 14 ) negative ] , CD20 CD5 . Adequate renal function ( Creatinine clearance &gt; 40 mL/min ) , preserve diuresis . Adequate liver function : alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) value , total bilirubin &lt; 2 mg/dL , unless directly attributable patient 's tumor . Hepatitis B core antibody ( HBcAb ) positive/HBsAg negative/HBVDNA negative patient may enrol correct antiviral prophylaxis administer least 2 week initiate protocol treatment . Written informed consent . Human immunodeficiency virus ( HIV ) positive . Previous treatment lymphoma Medical condition organ injury could interfere administration therapy . Active bacterial , viral , fungal infection require systemic therapy . Seizure disorder require anticonvulsant therapy . Severe chronic obstructive pulmonary disease hypoxemia . History severe cardiac disease : New York Heart Association ( NYHA ) functional class IIIIV , myocardial infarction within 6 month , ventricular tachyarrhythmias , dilatative cardiomyopathy , unstable angina . Uncontrolled diabetes mellitus . Active secondary malignancy . Known hypersensitivity anaphylactic reaction murine antibody protein , Bendamustine mannitol . Major surgery within 4 week study Day 1 . HBsAg+ HCVAb+ patient active viral replication ( HCVRNA+ AST &gt; 2 x normal limit ) Any coexist medical psychological condition would preclude participation study compromise patient 's ability give inform consent , may affect interpretation result , render patient high risk treatment complication . CNS involvement ( diagnostic lumbar puncture perform patient blastoid variant MCL )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MCL</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
	<keyword>Older</keyword>
</DOC>